Interviews

Nonprofits are finding new ways to address market gaps and develop treatments for rare diseases with little commercial attraction.

Discover Henlius’ groundbreaking achievements, and their mission to deliver affordable, innovative drugs worldwide through strategic partnerships.

Discover Henlius’ groundbreaking achievements, and their mission to deliver affordable, innovative drugs worldwide through strategic partnerships.

Medtech Insight asked three leading AI experts, Verily’s Andrew Trister, Ferrum Health’s Pelu Tran and Hologic’s Jennifer Schneiders, to offer their perspectives on the future of AI in health care.

The Swiss giant’s blockbuster gene therapy is currently only administered intravenously into patients with spinal muscular atrophy under two years of age. Its intrathecal candidate, called OAV-101, has just passed a Phase III test which could expand its use in children and young adults.

Original innovation in drug development is vital for Chinese pharmas to grow into international majors within a decade, while originality is not necessarily restricted to the first-in-class category, Xingli Wang, head of Fosun Pharma’s Global R&D, shares his thoughts with Scrip.

Medtech Insight spoke with executives from Spanish medtech firm Time is Brain about their wearable device that monitors stroke victims in real time, potentially saving lives.

Interim results from an international Phase II study with its prolactin inhibiting antibody have boosted HopeMed’s confidence in its first-line potential in the chronic disorder, the Chinese venture's CEO tells Scrip.

Ex-Janssen India chief and BSV CEO Sanjiv Navangul shares with Scrip glimpses of his life and professional journey including chasing the IAS dream early on, the heady days at Hoechst with a stint in Moscow, challenges around Sirturo’s debut and unprecedented preps that fueled Januvia’s big run during his innings at MSD.

Oscotec co-CEO Taeyoung Yoon highlights anti-resistance and anti-tau therapies as the Korean bioventure’s next possible blockbuster candidates after the landmark US approval of lazertinib for lung cancer.